FOLH1 and prostate carcinoma: In a recent interim analysis of a phase 2 prospective clinical trial involving intermediate to high-risk prostate cancer patients undergoing radical prostatectomy and RGS using 99mTc-PSMA I&S, the reported specificity on a per region and per patient basis was 99% and 100%, respectively [53].